Why is phenotyping performed for a patient who will receive daratumumab?

Master the CAMLPR Transfusion Test with interactive questions and detailed explanations. Boost your knowledge and ensure you're exam-ready with comprehensive study resources!

Multiple Choice

Why is phenotyping performed for a patient who will receive daratumumab?

Daratumumab binds CD38 on red cells and can cause panagglutination in antibody screening tests, making it hard to see any underlying antibodies. Because the safety of transfusion hinges on knowing the patient’s blood group, phenotype testing is performed to determine the ABO group so compatible blood can be chosen even when serologic testing is compromised. In other words, establishing the ABO phenotype before transfusion ensures you provide an ABO-compatible unit despite the interference from daratumumab.

Daratumumab binds CD38 on red cells and can cause panagglutination in antibody screening tests, making it hard to see any underlying antibodies. Because the safety of transfusion hinges on knowing the patient’s blood group, phenotype testing is performed to determine the ABO group so compatible blood can be chosen even when serologic testing is compromised. In other words, establishing the ABO phenotype before transfusion ensures you provide an ABO-compatible unit despite the interference from daratumumab.

More practice questions